IL6 and COVID-19: The present review is aimed at overviewing the available experience on the effectiveness and safety of immunomodulatory therapies for the treatment of COVID-19 in SOT recipients, with focus on IL-6-targeted agents in view of the more extensive evidence as compared to other therapeutic groups.